ResMed (NYSE:RMD – Get Rating) and Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ResMed and Bluejay Diagnostics, as provided by MarketBeat.com.
Get
ResMed alerts:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| ResMed | 0 | 4 | 5 | 0 | 2.56 |
| Bluejay Diagnostics | 0 | 0 | 1 | 0 | 3.00 |
ResMed presently has a consensus price target of $267.00, suggesting a potential upside of 28.29%. Bluejay Diagnostics has a consensus price target of $10.00, suggesting a potential upside of 2,532.28%. Given Bluejay Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Bluejay Diagnostics is more favorable than ResMed.
Valuation and Earnings
This table compares ResMed and Bluejay Diagnostics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| ResMed | $3.58 billion | 8.52 | $779.44 million | $5.35 | 38.90 |
| Bluejay Diagnostics | N/A | N/A | -$3.49 million | ($0.44) | -0.86 |
ResMed has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
64.7% of ResMed shares are owned by institutional investors. Comparatively, 0.9% of Bluejay Diagnostics shares are owned by institutional investors. 1.4% of ResMed shares are owned by company insiders. Comparatively, 45.3% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares ResMed and Bluejay Diagnostics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| ResMed | 21.70% | 25.75% | 17.09% |
| Bluejay Diagnostics | N/A | -47.07% | -43.59% |
Summary
ResMed beats Bluejay Diagnostics on 9 of the 12 factors compared between the two stocks.
About ResMed
(Get Rating)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
About Bluejay Diagnostics
(Get Rating)
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
